Literature DB >> 24652426

The use of traditional Chinese medicine among breast cancer patients: implications for the clinician.

Kar Yong Wong1, Ern Yu Tan, Juliana J C Chen, Christine Teo, Patrick M Y Chan.   

Abstract

INTRODUCTION: Traditional Chinese Medicine or Traditional Complementary Medicine (TCM) is commonly used in our culture. There are several concerns regarding its use in patients undergoing conventional treatments for breast cancer. In this study, we aimed to evaluate the prevalence and pattern of TCM use among our breast cancer patients, and to identify patients who were most likely to choose TCM.
MATERIALS AND METHODS: A total of 300 patients on active follow-up with Breast Service at Tan Tock Seng Hospital were interviewed using a structured questionnaire.
RESULTS: A total of 35% (104 of 296) of patients reported using TCM. The majority of the patients were introduced to TCM by family and friends following the diagnosis of breast cancer. All except 3 patients continued with recommended conventional therapy although most did not inform their clinicians of TCM use. None of the patients reported any serious adverse events and 75% of them perceived a benefit from TCM use. Younger patients and those of Chinese ethnicity were more likely to use TCM (P <0.01 and P = 0.03 respectively). There was no significant difference in the dialect group, religious beliefs and educational level between the 2 groups (P >0.05).
CONCLUSION: TCM use is common among our breast cancer patients, particularly the younger women. However, most patients do not inform their clinicians of TCM use while on recommended conventional therapies. It is therefore important for clinicians to initiate discussions regarding TCM use in order to be aware of potential unwanted drug interactions.

Entities:  

Mesh:

Year:  2014        PMID: 24652426

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  2 in total

1.  Effects of Astragaloside IV on treatment of breast cancer cells execute possibly through regulation of Nrf2 via PI3K/AKT/mTOR signaling pathway.

Authors:  Xiao-Qing Zhang; Chang Yao; Wei-He Bian; Xu Chen; Jing-Xian Xue; Zhi-Yuan Zhu; Yu Ying; Yan Lei Xu; Cong Wang
Journal:  Food Sci Nutr       Date:  2019-09-18       Impact factor: 2.863

2.  An innovative anti-cancer Chinese herbal formula exhibited multi-targeted efficacies in metastatic breast cancer mouse model.

Authors:  Grace Gar-Lee Yue; Julia Kin-Ming Lee; Ben Chung-Lap Chan; Hin-Fai Kwok; Sandy Wan-Heng Hoi; Daniel Man-Yuen Sze; Kwok-Pui Fung; Ping-Chung Leung; Clara Bik-San Lau
Journal:  Chin Med       Date:  2018-12-22       Impact factor: 5.455

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.